Replies to post #146735 on Cytodyn Inc (CYDY)

[CTMedic]

2020,

I am struggling to follow your suggestion:

EVERYBODY SHOULD READ JULY 20, 2020 PRESS RELEASE ISSUED BY CYDY

I have read a lot of Cytodyn PRs. Perhaps too many, as some have complained.

The only PR that continues to capture my attention is that of December 24.

https://www.cytodyn.com/investors/news-events/press-releases/detail/493/fda-provides-guidance-for-adding-an-open-label-extension-to

The germane section is:

FDA Provides Guidance for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 Patients Until Trial Data is Unblinded

Download as PDFDecember 24, 2020 7:46pm EST
The agency will also consider eINDs for patients in other hospitals who qualify for inclusion criteria similar to CD12

The CD12 trial completed enrollment with 394 patients on December 16

From this, we know that the trial completed January 13. We are now one month/31 days from trial completion.

We are more than halfway to the interval which Novartis took to announce failure of the con-covid trial (61 days), and more than the 28 days that it took for topline results of the positive CD10 trial,(statistically significant reduction in NEWS2/clinical worsening and 60% reduced SAEs!).

I expect that the next PR will announce positive results from CD12 with EUA or approval.

You may find it helpful to look backward, but I'm looking forward.

Nonetheless, perhaps you want us to look at the PR from another company. I do not see a July 20 PR listed, for what it's worth.

Impressive Results From CytoDyn’s Phase 2 Covid-19 Trial
Jul 21, 2020 6:00am EDT

CytoDyn’s CEO Dr. Pourhassan to Appear on DrBeen Webcast Tomorrow July 18, 2020
Jul 17, 2020 5:31pm EDT